{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:07:58Z","timestamp":1789103278901,"version":"build-2803163510"},"reference-count":6,"publisher":"Royal College of Psychiatrists","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Br J Psychiatry"],"DOI":"10.1192\/bjp.2026.10788","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:41:06Z","timestamp":1789101666000},"page":"1-2","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":0,"title":["Clozapine monitoring reform: an access issue, not only a safety question"],"prefix":"10.1192","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0845-5949","authenticated-orcid":false,"given":"Laiba","family":"Javed","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00gt6pp04","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Health Sciences Lahore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"S0007125026107880_ref2","doi-asserted-by":"publisher","DOI":"10.1093\/schizbullopen\/sgac042"},{"key":"S0007125026107880_ref4","doi-asserted-by":"publisher","DOI":"10.1017\/ipm.2026.10183"},{"key":"S0007125026107880_ref6","unstructured":"6 UK Parliament. Clozapine: Side Effects. Written Question UIN 45332, Answered by Karin Smyth. UK Parliament, 2025 (https:\/\/questions-statements.parliament.uk\/written-questions\/detail\/2025-04-08\/45332 [cited 19 Jul 2026])."},{"key":"S0007125026107880_ref5","unstructured":"5 US Food and Drug Administration. FDA Removes Risk Evaluation and Mitigation Strategy (REMS) Program For the Antipsychotic Drug Clozapine. FDA, 2025 (https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-removes-risk-evaluation-and-mitigation-strategy-rems-program-antipsychotic-drug-clozapine [cited 19 Jul 2026])."},{"key":"S0007125026107880_ref1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2024.150"},{"key":"S0007125026107880_ref3","first-page":"7996","article-title":"MHRA to review blood monitoring requirements for clozapine patients","volume":"314","author":"Jankovi\u0107","year":"2025","journal-title":"Pharm J"}],"container-title":["The British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125026107880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:41:15Z","timestamp":1789101675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125026107880\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":6,"alternative-id":["S0007125026107880"],"URL":"https:\/\/doi.org\/10.1192\/bjp.2026.10788","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"\u00a9 The Author(s), 2026. Published by Cambridge University Press on behalf of Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}